Mitsubishi Tanabe cuts guidance on low income

24 November 2008

Japan's Mitsubishi Tanabe posted reduced profit like-for-like in the first half of the fiscal year ending in March, 2009, due to 4.7 billion yen ($47.5 million) of pay-outs to employees who opted for early retirement.

Net profit fell 19.5% to 16.38 billion yen, in part because of the above exceptional costs, but also an 18% increase in R&D expenses to 37.62 billion yen, artificial sales increases caused by stock build-ups in the previous year and a drop in revenue.

Turnover dipped 0.7% to 206.34 billion yen, primarily consisting of pharmaceutical sales of 190.95 billion yen, which were down 1%. The firm says this was mainly due to National Health Insurance price revisions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight